The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) drugs in development market research report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) by 17 companies/universities/institutes. The top development phase for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) is phase ii with six drugs in that stage. The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline has 18 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market are: GSK, Bio-Thera Solutions and Sana Biotechnology.
The key targets in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market include Interleukin 5, B Lymphocyte Antigen CD19, and B Lymphocyte Antigen CD20.
The key mechanisms of action in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline product include Interleukin 5 Inhibitor with five drugs in Phase III. The Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products include four routes of administration with the top ROA being Intravenous and seven key molecule types in the Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) pipeline products market including Monoclonal Antibody, and Gene-Modified Cell Therapy.
Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) overview
Wegener polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factors include age. Treatment includes immunosuppressants and corticosteroids.
For a complete picture of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
